24.61

5.80% 1.35

After Hours: 25.00 0.39 +1.58%

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $24.61, with a volume of 691.90K. It is up +5.80% in the last 24 hours and down -12.58% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$23.26

Open:

$23.54

24h Volume:

691.90K

Relative Volume:

0.87

Market Cap:

$1.59B

Revenue:

$32.08M

Net Income/Loss:

$-169.77M

P/E Ratio:

-8.66

EPS:

-2.8418

Net Cash Flow:

$-147.70M

1W Performance:

+2.76%

1M Performance:

-12.58%

6M Performance:

-30.75%

1Y Performance:

-30.87%

1-Day Range:

$23.45

$24.62

1-Week Range:

$22.05

$25.20

52-Week Range:

$20.32

$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

170

Twitter

@stoketx

Next Earnings Date

2026-11-03

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	24.61	1.59B	32.08M	-169.77M	-147.70M	-2.8418
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-21-26	Resumed	JP Morgan	Overweight
Jul-13-26	Initiated	Goldman	Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-05-26	Initiated	Guggenheim	Buy
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Oct 13, 2026

Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock By Investing.com - Investing.com Nigeria

Oct 13, 2026

Stoke therapeutics CMO Barry Ticho sells $27,493 in stock By Investing.com - Investing.com Canada

Oct 13, 2026

Oct 02, 2026

At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK). - Stock Titan

Oct 02, 2026

Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK). - Stock Titan

Oct 02, 2026

Under a trading plan, Stoke Therapeutics (STOK) medical chief sells 1,051 shares. - Stock Titan

Oct 02, 2026

Sep 30, 2026

BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - kalkinemedia.com

Sep 30, 2026

A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan

Sep 30, 2026

Sep 26, 2026

Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Sep 25, 2026

Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan

Sep 25, 2026

Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media

Sep 25, 2026

Sep 23, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2026

Sep 16, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance

Sep 16, 2026

Sep 11, 2026

Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us

Sep 11, 2026

Sep 10, 2026

Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com

Sep 10, 2026

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria

Sep 10, 2026

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Canada

Sep 10, 2026

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com India

Sep 10, 2026

Sep 09, 2026

Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India

Sep 09, 2026

Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com Canada

Sep 09, 2026

STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView

Sep 09, 2026

STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView

Sep 09, 2026

Stoke Therapeutics (STOK) Institutional Ownership 2026 $STOK - MarketBeat

Sep 09, 2026

Sep 08, 2026

Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat

Sep 08, 2026

Sep 06, 2026